Study on Pembrolizumab With or Without Sacituzumab Tirumotecan for Treating Non-Small Cell Lung Cancer After Surgery

Inclusion Criteria

• Diagnosed with a specific type of non-small cell lung cancer (NSCLC) that can be surgically removed and is at Stage II, IIIA, or IIIB with certain lymph node involvement.
• Confirmed that treatment targeting the EGFR gene is not suitable as the main therapy.
• Able to undergo surgery as determined by the doctor and surgeon.
• Can receive pembrolizumab and a specific type of chemotherapy before surgery.
• After surgery, the cancer was not completely removed, as confirmed by a local pathology review.
• Tumor tissue from surgery must be available for testing specific markers before starting the next phase of treatment.
• Confirmed to be free of disease based on recent imaging tests before starting the next phase of treatment.
• Any side effects from previous cancer treatments must have improved to a mild level or returned to baseline.
• HIV-positive participants must have well-controlled HIV with medication.
• Participants with hepatitis B must have been treated for at least 4 weeks and have an undetectable viral load.
• Participants with a history of hepatitis C must have an undetectable viral load at least 4 weeks before starting the study treatment.

Exclusion Criteria

• Have certain types of lung cancer, such as those involving the superior sulcus, large cell neuro-endocrine cancer, sarcomatoid tumor, or small cell elements.
• Have specific genetic changes in the cancer, like ALK gene rearrangements.
• Have moderate to severe nerve damage.
• Have severe eye conditions that affect healing.
• Have active inflammatory bowel disease needing medication or a history of it.
• Have uncontrolled heart or blood vessel diseases, including severe heart failure, recent heart attack, or serious heart rhythm problems.
• Have received prior treatment for the current lung cancer diagnosis.
• Have had cancer treatments, including experimental drugs, within 4 weeks before starting the study.
• Have had radiation therapy within 2 weeks before starting the study or have side effects from it needing steroids.
• Have received a live vaccine within 30 days before starting the study.
• Have used an experimental device or drug within 4 weeks before starting the study.
• Have an immune system deficiency or are on high-dose steroids or other immune-suppressing drugs.
• Have another active cancer needing treatment in the past 5 years.
• Have an active autoimmune disease needing treatment in the past 2 years.
• Have a history of lung inflammation needing steroids or current lung inflammation.
• Have an active infection needing treatment.
• Have HIV with a history of certain cancers.
• Have active hepatitis B and C infections.
• Have a severe allergy to sacituzumab tirumotecan or similar drugs.
• Have had a tissue or organ transplant.
• Have not fully recovered from major surgery or have ongoing surgical issues.